


-36-

# CLAIMS

1. The use of a 2-amino-benzothiazole, having the formula



a *N*-oxide, salt, stereoisomeric form, racemic mixture, prodrug, ester or metabolite

5 thereof, wherein

R<sub>1</sub> is hexahydrofuro[2,3-*b*]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino;

10 R<sub>2</sub> is hydrogen or C<sub>1-6</sub>alkyl;

L is a direct bond, -O-, C<sub>1-6</sub>alkanediyl-O- or -O-C<sub>1-6</sub>alkanediyl;

R<sub>3</sub> is phenylC<sub>1-4</sub>alkyl;

R<sub>4</sub> is C<sub>1-6</sub>alkyl;

R<sub>5</sub> is hydrogen or C<sub>1-6</sub>alkyl;

15 R<sub>6</sub> is hydrogen or C<sub>1-6</sub>alkyl;

in the manufacture of a medicament useful for inhibiting mutant HIV protease in a mammal infected with said mutant HIV protease.

2. The use according to claim 1 wherein

20 R<sup>2</sup> is hydrogen;

R<sup>3</sup> is phenylmethyl;

R<sup>4</sup> is C<sub>1-4</sub>alkyl, preferably isobutyl;

R<sup>5</sup> is hydrogen or methyl;

R<sup>6</sup> is hydrogen or methyl.

25

3. The use according to claim 1 or 2 wherein R<sup>5</sup> is methyl or hydrogen and R<sup>6</sup> is hydrogen

4. The use according to any one of claims 1 to 3 wherein both R<sup>5</sup> and R<sup>6</sup> are hydrogen.

30

5. The use according to any one of claims 1 to 4 wherein -L-R<sup>1</sup> is -O-(hexahydrofuro[2,3-*b*]furanyl), -O-tetrahydrofuranyl, -O-methyl-(optionally substituted phenyl), -O-methyl-pyridinyl, -O-methyl-thiazolyl, -O-methyl-thiazolyl, -methyl-O-(optionally substituted phenyl) or optionally substituted phenyl.

35


-37-

6. The use according to any one of claims 1 to 5 wherein the compound is  
{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
5 carbamic acid thiazol-5-ylmethyl ester;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
{1-benzyl-3-[(2-dimethylamino-benzothiazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-  
propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
10 {3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid benzyl ester;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
2-(2,6-dimethyl-phenoxy)-acetamide;  
{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
15 carbamic acid pyridin-3-ylmethyl ester;  
3-amino-N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-  
hydroxypropyl}-2-methyl-benzamide;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
3-hydroxy-2-methyl-benzamide;  
20 {3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid tetrahydro-furan-3-yl ester;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
2-methyl-benzamide;  
N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
25 propyl}-2-(2,6-dimethyl-phenoxy)-acetamide;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
3-fluoro-2-methyl-benzamide;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
2-(4-aminomethyl-2,6-dimethyl-phenoxy)-acetamide;  
30 {1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
propyl}-carbamic acid thiazol-5-ylmethyl ester;  
3-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-  
sulfonyl)-amino]-propyl}-2-methyl-benzamide;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
35 propyl}-carbamic acid tetrahydro-furan-3-yl ester;  
N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
propyl}-3-hydroxy-2-methyl-benzamide;

-38-

- N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
2-(4-iodo-2,6-dimethyl-phenoxy)-acetamide;  
2-(4-aminomethyl-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-  
methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;  
5 2-(4-amino-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-  
methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;  
N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
propyl}-4-bromo-2-methyl-benzamide;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
10 propyl}-carbamic acid oxazol-5-ylmethyl ester;  
4-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-  
sulfonyl)-amino]-propyl}-3-hydroxy-2-methyl-benzamide;  
or a salt, or a stereoisomeric form thereof.
- 15 7. The use according to any one of claims 1 to 6 wherein the mutant HIV protease has  
at least one mutation at a position selected from 10, 71 and 84.
8. The use according to any one of claims 1 to 7 wherein the fold resistance of the  
mutant HIV protease for the compound described in any one of claims 1 to 6 ranges  
20 between 0.01 and 100.

9. A compound having the formula



- a *N*-oxide, salt, stereoisomeric form, racemic mixture, prodrug, ester or metabolite  
25 thereof, wherein  
R<sub>1</sub> is hexahydrofuro[2,3-*b*]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or  
phenyl optionally substituted with one or more substituents independently  
selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or  
di(C<sub>1-4</sub>alkyl)amino;  
30 R<sub>2</sub> is hydrogen or C<sub>1-6</sub>alkyl;  
L is a direct bond, -O-, C<sub>1-6</sub>alkanediyl-O- or -O-C<sub>1-6</sub>alkanediyl;  
R<sub>3</sub> is phenylC<sub>1-4</sub>alkyl;  
R<sub>4</sub> is C<sub>1-6</sub>alkyl;  
R<sub>5</sub> is hydrogen or C<sub>1-6</sub>alkyl;  
35 R<sub>6</sub> is hydrogen or C<sub>1-6</sub>alkyl;

-39-

provided that the compound is other than :

- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid benzyl ester;  
{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid pyridin-3-ylmethyl ester;  
5 { (1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid thiazol-5-ylmethyl ester;  
{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-(2,6-dimethyl-phenoxy)-acetamide;  
10 3-amino-{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-methyl-benzamide;  
4-amino-{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-methyl-benzamide;  
5-amino-{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-methyl-benzamide;  
15 N-{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-methyl-benzamide;  
N-{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-4-hydroxy-2-methyl-benzamide;  
20 N-{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-3-hydroxy-2-methyl-benzamide; and  
{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid (S)-(tetrahydrofuran-3-yl) ester.

- 25 10. A compound according to claim 9 wherein R<sup>1</sup> is hexahydrofuro[2,3-b]furanyl or oxazolyl.

- 11 A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, and L is a direct bond.

30

12. A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino; and L is -O-.

35

13. A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, or phenyl substituted with one or more substituents

-40-

independently selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino; and L is C<sub>1-6</sub>alkanediyl-O- whereby the -O- is attached to the nitrogen of the amide.

- 5 14. A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino; and L is -O-C<sub>1-6</sub>alkanediyl whereby -O- is attached to the R<sup>1</sup> group.
- 10 15. A compound according to any one of claims 9 to 14 wherein at least one of R<sub>5</sub> and R<sub>6</sub> is C<sub>1-6</sub>alkyl.
- 15 16. A compound according to any one of claims 9 to 15 wherein R<sup>2</sup> is hydrogen; R<sup>3</sup> is phenylmethyl; R<sup>4</sup> is C<sub>1-4</sub>alkyl.
17. a compound according to any one of claims 9 to 16 having the formula  
{ 1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl }-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- 20 { 1-benzyl-3-[(2-dimethylamino-benzothiazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl }-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
N-{ 1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl }-2-(2,6-dimethyl-phenoxy)-acetamide;  
N-{ 3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl }-
- 25 3-fluoro-2-methyl-benzamide;
- N-{ 3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl }-2-(4-aminomethyl-2,6-dimethyl-phenoxy)-acetamide;
- { 1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl }-carbamic acid thiazol-5-ylmethyl ester;
- 30 3-amino-N-{ 1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl }-2-methyl-benzamide;
- { 1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl }-carbamic acid tetrahydro-furan-3-yl ester;
- N-{ 1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl }-3-hydroxy-2-methyl-benzamide;
- 35 N-{ 3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl }-2-(4-iodo-2,6-dimethyl-phenoxy)-acetamide;

-41-

- 2-(4-aminomethyl-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;  
2-(4-amino-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;  
5 N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-4-bromo-2-methyl-benzamide;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid oxazol-5-ylmethyl ester;  
4-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-3-hydroxy-2-methyl-benzamide;  
10 a salt thereof, or a stereoisomeric form thereof.
18. A compound according to claim 9 or 10 having the formula  
{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
15 carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
{1-benzyl-3-[(2-dimethylamino-benzothiazole-6-sulfonyl)-isobutyl-amino]-2-hydroxypropyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
20 or a salt or stereoisomeric form thereof.